ROSSELL-TECHSYS
26.8.2020 12:32:14 CEST | Business Wire | Press release
Rossell Techsys (Division of Rossell India Limited) has been named a global Supplier of the Year by aerospace major Boeing. The award in the Production category is for being instrumental in the design, modification or production of a product, for 2019.
“Rossell Techsys contributes high quality components for some of Boeing’s most advanced platforms and we are proud to partner with them. Achieving the Supplier of the Year distinction for the second time is an acknowledgement of Rossell Techsys’ capabilities,” said Salil Gupte, president, Boeing India . “Boeing continues to grow a globally competitive supplier base in India, with strong partnerships that are aligned with the government’s Aatmanirbhar Bharat vision,” he added.
“We are delighted and grateful to receive the Supplier of the Year award from Boeing, for the second time in five years. Our long-term strategy of targeted investments in aerospace and defense continues to reap rich dividends, enhancing customer confidence and trust. We are thankful to Boeing for this recognition,” said Rishab Mohan Gupta, Director, Rossell India Limited.
“We are humbled to be chosen by Boeing for this award, among 12,000 active global suppliers. This award is a testimony to Rossell Techsys’ manufacturing capabilities and customer focus. We believe this is also a recognition of the rising stature of India in global Aerospace and Defense manufacturing,” said Prabhat Kumar Bhagvandas, Chief Executive Officer, Rossell Techsys.
Rossell Techsys is based in Bangalore, India, and supplies engineering, manufacturing, test, and product support solutions to global aerospace and defense OEMs. For Boeing, Rossell Techsys provides manufacturing services for Interconnect Systems, such as wire harnesses and electrical/cockpit panels. Key Boeing platforms supported by Rossell Techsys include the F/A-18, F-15, AH-64, CH-47, V-22, KC-46, P-8, and T-7A.
About Rossell Techsys
Rossell Techsys is the Aerospace & Defense Division of Rossell India Limited, a public listed company. It is at the forefront of the “Made in India’ brand of excellence committed to “finish and finesse”. It is AS9100, ISO 9001, ISO 14001, ISO 45001, ISO 27001, ISO 37001 certified, and ISO 31000 compliant. It has instituted paperless, green manufacturing processes in its LEED rated 250,000-square-foot facility.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200826005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom